RxDoctor Payments Data

Brian Baturin, MD

Cardiovascular Disease · Washington, DCNPI 1972982478

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (46.4%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Abbott at 54.5% of the total. Reporting peaked in 2024 at $1,681 and has fallen 97.9% since, to $35 in 2025.

$3,082in general payments, 2019–2025

Across 50 payments — averaging $61.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$452
  • Astellas Pharma US Inc$406
  • Pfizer$143
  • E.r. Squibb & Sons, L.L.C.$124
  • Preventice Services, LLC$111
  • plus $165 from 5 others

What the payments were for

  • Travel & lodging$1,42946%
  • Food & beverage$1,27341%
  • Education$38112%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,082 in reported general payments places this provider in the 60th percentile of 105 cardiovascular disease providers in District of Columbia.

See all cardiovascular disease providers in District of Columbia

Medicare billing

Part B allowed, 2024
$170,588
Medicare patients
1,902
Services billed
2,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$36,674
EntrestoSacubitril/Valsartan24$24,678
Rosuvastatin Calcium28$542
Amlodipine Besylate20$188
Metoprolol Succinate23$138
Atorvastatin Calcium14$84
Spironolactone26$74
Carvedilol12$65
Ezetimibe13$62
Furosemide12$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$24$24,67824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 105 cardiovascular disease providers in District of Columbia.

Other cardiovascular disease in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →